Please assess the completion status of the following clinical trial:

Trial Title: REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject must give written informed consent prior to any study related activities~* Subject age must be between 18 and 55 (both included)~* The subject must have MS according to McDonald criteria~* The subject must have disability equivalent to EDSS of 5.5 or less~* The subject must have been treated with any IFN-β preparation for at least 12 months at any time~* The subject must have been shown to be NAb positive and without no in vivo mRNA MxA response within the last 12 months~* The subject must be prepared and considered able to follow the protocol~Exclusion Criteria:~* The subject must not have conditions that might give rise to similar symptoms as MS~* The subject must not have received any immunomodulatory or immunosuppressive treatment (other than IFN-β or glatiramer acetate) 6 months prior to the screening visit~* The subject must not have received mitoxantrone, cyclophosphamide, treosulphane, natalizumab, daclizumab, rituximab, alemtuzumab, cladribine, or any experimental therapy at any time~* The subject must not have undergone previous total body irradiation, total lymphoid irradiation, stem cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.~* The subject must not have received treatment with glucocorticoids or ATCH later than 2 month prior to the screening visit~* The subject must not have alcohol and drug dependency~* The subject must not have cardiac or renal insufficiency~* The subject must not have any systemic disease that can influence the subject's safety or compliance~* Subjects may be male or female. Women of child-bearing potential must be sexually inactive or practice a medically acceptable method of birth control. Acceptable methods include oral contraceptive, contraceptive patch, long-acting injectable contraceptive, or double-barrier method (condom or IUD with spermicide)~* The subject must not have known or suspected allergy to IFN-α~* The subject must not have participated in any other study within 3 months prior to the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- IFN-alfa (Type: EXPERIMENTAL): One single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c.
- Interferon-beta (Type: EXPERIMENTAL): One single injection of IFN-beta followed by blood test for MxA9.12 hours after injection

Based on this trial design, predict the completion outcome and termination type (if applicable).